Nanexa enters EUR 1.165 billion global licensing deal with Novo Nordisk for long-acting injectables
Bitget2026/09/24 16:26- Nanexa entered a global exclusive license and collaboration agreement with Novo Nordisk for its PharmaShell drug-delivery platform.
- Deal targets long-acting injectable peptide drugs for obesity, type 2 diabetes, and other cardiometabolic indications.
- Novo secured rights for up to five development programs, aiming for monthly and quarterly dosing profiles.
- Nanexa is eligible for up to EUR 1.165 billion, including EUR 615 million in upfront and development and regulatory milestones.
- Agreement also includes sales milestones and low single-digit royalties on future product sales.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
WikiLeaks Founder Julian Assange Welcomes Daughter With Terminator Quote
Crypto prices
More
